Quantum Fuel Systems (Nasdaq:QTWW) delivers hydrogen dispensing system to Linde, Cerulean Pharma Inc. (Nasdaq:CERU), Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE)

Quantum Fuel Systems Technologies Worldwide Inc. (Nasdaq:QTWW) delivers hydrogen dispensing system to Linde.  Quantum Fuel Systems (Nasdaq:QTWW) in partnership with Linde North America, announces the first hydrogen dispensing system that measures hydrogen mass with connectivity to retail interface and user friendly payment features. The system was installed in West Sacramento and was unveiled at a grand opening hosted by the California Fuel Cell Partnership, Ramos Oil and Linde. This is the first public accessible Hydrogen refueling station that has demonstrated SAE compliant fast fill performance with accurate mass flow measurement, the company said. QTWW traded in the green and closed at  $ 2.16 for the day. The stock saw a change of $ 0.35(16.20%) with a volume of 488,503 shares. QTWW has a market cap of $ 58.31M.

 

Cerulean Pharma Inc. (Nasdaq:CERU) completes enrollment in Phase 1b/2 study of CRLX101, Avastin. Cerulean Pharma announced completion of enrollment of 22 patients in a Phase 1b/2 clinical proof of principle trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin in relapsed renal cell carcinoma. This study is an investigator-sponsored trial being conducted by the University of Pennsylvania and Thomas Jefferson University Hospital with support from Cerulean. The Principal Investigator is Dr. Stephen Keefe of the University of Pennsylvania Abramson Cancer Center. CERU closed for the day at $ 6.24 yesterday. Today it is trading with a change of $ - 0.25.  CERU’s trailing 12 month’s profit margin is not available and for the same period, its operating margin is -18,581.39%.

 

 Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) initiates Phase 3 study of rhGUS, UX003. Ultragenyx Pharmaceutical announced the dosing of the first patient in the pivotal Phase 3 study of recombinant human beta-glucuronidase, or rhGUS, UX003, an investigational therapy for the treatment of Mucopolysaccharidosis 7. The primary objective of the study is to determine the efficacy of rhGUS as determined by the reduction in urinary GAG excretion after 24 weeks of treatment. The Phase 3 study will also evaluate the safety and tolerability of rhGUS, pulmonary function, walking, stair climb, shoulder flexion, fine and gross motor function, hepatosplenomegaly, cardiac size and function, visual acuity, patient and caregiver assessment of most significant clinical problems, global impressions of change, a multi-domain responder index, and other endpoints. In Nasdaq, RARE traded with a change of $0.76 and closed for the day at $ 39.76 with a volume of 50,030 shares. RARE‘s return on assets in last one year was  -22.07% and return on equities -42.19%.